VCANBIO(SH:600645)2018-10-29 16:00Financial Performance - Net profit attributable to shareholders increased significantly by 1,116.90% to CNY 334,556,709.91 for the first nine months of the year[6] - Operating revenue for the first nine months rose by 1.23% to CNY 971,345,455.23 compared to the same period last year[6] - Basic and diluted earnings per share both increased to CNY 0.84, up 1,100.00% compared to the previous year[7] - The net profit attributable to shareholders increased by 1116.90% year-on-year, while the net profit excluding non-recurring gains and losses rose by 489.84%[11] - The company reported a net loss of ¥379,077,509.64, an improvement from a loss of ¥713,634,219.55 in the previous period[21] - Total revenue for Q3 2018 was CNY 327,526,831.54, a slight increase from CNY 322,365,607.18 in Q3 2017, representing a growth of approximately 1.0%[28] - Net profit for Q3 2018 was CNY 26,459,807.02, down from CNY 31,887,216.87 in Q3 2017, reflecting a decrease of approximately 17.5%[29] - The total profit for the first nine months was 75,690,044.25 CNY, a recovery from a loss of -75,037,435.90 CNY in the same period last year[33] Assets and Liabilities - Total assets increased by 6.45% to CNY 4,659,152,934.87 compared to the end of the previous year[6] - The company has seen a significant increase in net assets attributable to shareholders, which rose by 10.71% to CNY 3,010,338,786.55 compared to the end of the previous year[6] - The company's total liabilities decreased slightly from ¥1,456,054,959.55 to ¥1,432,049,376.87, a reduction of approximately 1.6%[21] - Total assets as of Q3 2018 amounted to CNY 3,711,084,690.31, up from CNY 2,390,798,819.82 in the previous year, marking an increase of about 55.3%[25] - Total liabilities for Q3 2018 were CNY 1,007,639,249.56, compared to CNY 989,345,944.45 in Q3 2017, showing a slight increase of approximately 1.3%[25] - Owner's equity totaled CNY 2,703,445,440.75 in Q3 2018, significantly higher than CNY 1,401,452,875.37 in Q3 2017, representing an increase of about 92.9%[25] Cash Flow - The net cash flow from operating activities decreased by 28.92% to CNY 52,741,574.36 for the first nine months[6] - The company's cash flow from operating activities decreased by 28.92% to CNY 52,741,574.36, mainly due to increased employee compensation payments[13] - The net cash flow from investing activities increased by 126.99% to CNY 43,906,566.97, attributed to the proceeds from the disposal of stakes in certain companies[13] - Operating cash inflow for the year-to-date period reached ¥1,071,912,480.39, a slight increase from ¥1,035,835,289.87 in the previous year, reflecting a growth of approximately 3.7%[35] - Net cash flow from operating activities decreased to ¥52,741,574.36 from ¥74,201,546.04, indicating a decline of about 29% year-over-year[35] - Investment cash inflow totaled ¥327,814,111.65, down significantly from ¥786,005,373.69, representing a decrease of approximately 58%[36] - Cash flow from financing activities showed a net outflow of ¥58,545,107.03 compared to a net inflow of ¥106,836,063.81 in the previous year, indicating a shift in financing strategy[36] Shareholder Information - The total number of shareholders reached 45,024 by the end of the reporting period[9] - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., holds 18.93% of the shares[10] - The company plans to increase its shareholding by at least 2% and up to 3% of the total issued shares, extending the implementation period of this plan to November 2, 2018[16] Investments and Acquisitions - Investment income reached CNY 268,289,285.52, reflecting a significant increase of 3873.07% compared to the same period last year due to the disposal of stakes in Beijing Fan Sheng Zi Gene Technology Co., Ltd. and Beijing San You Li He Ze Biotechnology Co., Ltd.[12] - The company completed the acquisition of Shanghai Ao Yuan Medical Supplies Co., Ltd. and expanded its consolidation scope during the reporting period[14] - The company plans to transfer 67% of its stake in Zhejiang Sai Shang Pharmaceutical Technology Co., Ltd. for CNY 60 million, which has been approved by the shareholders' meeting[13] Other Financial Metrics - The company reported non-operating income of CNY 17,118,424.78 for the current period, contributing to overall profitability[8] - Other comprehensive income rose by 92.96% to CNY 38,623,918.26, mainly due to an increase in foreign currency translation differences[12] - The company incurred management expenses of 41,923,089.91 CNY for the first nine months, up from 31,155,002.43 CNY year-on-year[31] - The financial expenses for the first nine months were 4,465,866.96 CNY, down from 6,830,766.01 CNY in the previous year[31] - The company reported a tax expense of 0.38 CNY in the third quarter, indicating minimal tax liabilities[33] - The company received tax refunds amounting to ¥4,510,040.82, an increase from ¥3,280,312.50, showing improved tax recovery efforts[35]